Mimedx (MDXG) Free Cash Flow Growth (1y) (2012 - 2026)
Mimedx (MDXG) Free Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
- |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Mimedx |
549.99 Mn |
390.22 Mn |
41.62 Mn |
-73.41% |
| Date | Value |
|---|
| Mar 31, 2026 |
-73.41% |
| Dec 31, 2025 |
26.85% |
| Sep 30, 2025 |
57.30% |
| Jun 30, 2025 |
-37.10% |
| Mar 31, 2025 |
1.82% |
| Dec 31, 2024 |
135.18% |
| Sep 30, 2024 |
34.98% |
| Jun 30, 2024 |
202.82% |
| Mar 31, 2024 |
203.27% |
| Dec 31, 2023 |
127.82% |
| Sep 30, 2023 |
2,149.67% |
| Jun 30, 2023 |
320.86% |
| Mar 31, 2023 |
54.73% |
| Dec 31, 2022 |
131.71% |
| Sep 30, 2022 |
-89.45% |
| Jun 30, 2022 |
-383.50% |
| Mar 31, 2022 |
-19.97% |
| Dec 31, 2021 |
7.83% |
| Sep 30, 2021 |
209.73% |
| Jun 30, 2021 |
134.05% |
